Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @ImmuneOnc
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ImmuneOnc
-
Panelists including
@ImmuneOnc CEO@charlene_liao at#EastWestCEO conference ahead of#JPM20 agreed#ImmunoOncology will be driver of innovation in#Oncology over the next ten years.pic.twitter.com/AmXKwAKBH6
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Count-down to our panel on what's next in the oncology landscape. Don't miss it! Today at 1:45-2:15pm
#EastWestCEO conference.https://twitter.com/ImmuneOnc/status/1215785291757211648 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@ImmuneOnc@charlene_liao will join fellow CEOs to discuss new progress in#oncology. Our focus is on new therapies for#AML. Join us today at 1:45-2:15pm#EastWestCEO conference.https://twitter.com/ImmuneOnc/status/1215785291757211648 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Interested in what's next for
#oncology? If attending#JPM20, stop by#EastWestCEO first and hear what our CEO@charlene_liao and other biotech CEOs discuss. Sunday 1:45-2:15pm.https://twitter.com/ImmuneOnc/status/1215785291757211648 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We're excited to take part in
#EastWestCEO. See you there and have a great#JPM20!https://twitter.com/ImmuneOnc/status/1215785291757211648 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Heading to
#JPM20? First, join us at#EastWestCEO.@ImmuneOnc CEO@charlene_liao will be part of a panel discussing developments in the#oncology landscape on Sunday, 1:45-2:15pm. https://www.immune-onc.com/news pic.twitter.com/sTdWjxjmiW
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@ImmuneOnc, a#cancerimmunotherapy company, adds industry vets to executive team and advisory boards: Dr. Paul Woodard appointed CMO, Dr. An Song promoted to CSO, Dr. Zhengbin (Bing) Yao joins Board of Directors and Dr. Greg Cosma appointed to SAB.https://www.businesswire.com/news/home/20191119005329/en/Immune-Onc-Therapeutics-Prepares-Phase-Growth-New-Leadership …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@ImmuneOnc’s SVP of Development Sciences, An Song shared insights on a novel#cancerimmunotherapy target for#acutemyeloidleukemia (#AML) at the Precision:Blood Cancer R&D Summit in SF.@NeoSynthEventspic.twitter.com/Ur77Ji02OM
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Tomorrow,
@ImmuneOnc’s SVP of Development Sciences An Song will join leaders in cancer R&D as a featured speaker at the Precision:Blood Cancer R&D Summit in SF. Don’t miss her presentation on a novel target for#acutemyeloidleukemia (#AML), 12:00pm, 9/17.@NeoSynthEventsHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@ImmuneOnc CEO@charlene_liao discusses the untapped potential of#myeloid cell targeted therapies in#cancerimmunotherapy#SDDS2019pic.twitter.com/TZdzMB9m1V
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Day 2 of the Stanford Drug Discovery Symposium
#SDDS2019 is packed with leading edge research. Immune-Onc Therapeutics CEO@charlene_liao looks forward to an engaging talk as part of the Discovery Showcase later this am.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@ImmuneOnc is excited to participate in the Stanford Drug Discovery Symposium#SDDS2019. Congratulations to#SDDS2019 Lifetime Achievement awardee, John Martin, seen here with our CEO@charlene_liao and SVP, Development Sciences, An Song.pic.twitter.com/RBrMqzbBdD
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The research is the outcome of many years of collaboration between
@ImmuneOnc and the teams at@UTSWNews and@UTHealth. We are grateful to Alec Zhang, Zhiqiang An and Ningyan Zhang and their teams for their dedication and continued partnership.https://twitter.com/UTSWNews/status/1055557150343356416 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@ImmuneOnc aims to move novel#cancerimmunotherapy research in#AcuteMyeloidLeukemia (#AML) into first phase of clinical testing in 2019 based on research resulting from collaboration with@UTSWNews and@UTHealth.https://twitter.com/ImmuneOnc/status/1052629344437252096 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@ImmuneOnc names first target in its#cancerimmunotherapy portfolio based on work published today in@nature in collaboration with@UTSWNews and@UTHealth researchers describing a novel target for#AcuteMyeloidLeukemia (#AML) and a potential treatment approach.https://twitter.com/ImmuneOnc/status/1052629344437252096 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@ImmuneOnc is pleased to share new non-clinical research published today in@nature on a novel#cancerimmunotherapy target and potential treatment approach for#AcuteMyeloidLeukemia. The research is the outcome of many years of collaboration with the teams at@UTSWNews@UTHealth.https://twitter.com/ImmuneOnc/status/1052629344437252096 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Thank you
@endpts for the nice article!https://twitter.com/endpts/status/1042447350550147077 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Immune-Onc is proud to appoint Dr. Adrian Jubb as Chief Medical Officer and Dr. An Song as SVP of Development Sciences. Welcome to the team!https://www.businesswire.com/news/home/20180918005183/en/Immune-Onc-Therapeutics-Announces-Key-Executive-Appointments-Series …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are pleased to announce today Series B funding from new and existing investors:https://www.businesswire.com/news/home/20180918005183/en/Immune-Onc-Therapeutics-Announces-Key-Executive-Appointments-Series …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.